271 related articles for article (PubMed ID: 7848024)
1. Blood pressure effects of the angiotensin II receptor blocker, losartan.
Weber MA; Byyny RL; Pratt JH; Faison EP; Snavely DB; Goldberg AI; Nelson EB
Arch Intern Med; 1995 Feb; 155(4):405-11. PubMed ID: 7848024
[TBL] [Abstract][Full Text] [Related]
2. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components.
MacKay JH; Arcuri KE; Goldberg AI; Snapinn SM; Sweet CS
Arch Intern Med; 1996 Feb; 156(3):278-85. PubMed ID: 8572837
[TBL] [Abstract][Full Text] [Related]
3. Antihypertensive efficacy of the angiotensin II AT1-receptor antagonist losartan: results of a randomized, double-blind, placebo-controlled, parallel-group trial using 24-hour blood pressure monitoring. Ambulatory Blood Pressure Monitoring Study Group.
Byyny RL
Blood Press Suppl; 1996; 2():71-7. PubMed ID: 8913544
[TBL] [Abstract][Full Text] [Related]
4. Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist, in the treatment of hypertension.
Mallion JM; Goldberg AI
Blood Press Suppl; 1996; 2():82-6. PubMed ID: 8913546
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of losartan.
Goldberg A; Sweet C
Can J Cardiol; 1995 Aug; 11 Suppl F():27F-32F. PubMed ID: 7664215
[TBL] [Abstract][Full Text] [Related]
6. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
Palatini P; Dorigatti F; Mugellini A; Spagnuolo V; Varì N; Ferrara R; Bertocchi F
Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006
[TBL] [Abstract][Full Text] [Related]
7. Controlling blood pressure throughout the day: issues in testing a new anti-hypertensive agent.
Weber MA; Neutel JM; Smith DH
J Hum Hypertens; 1995 Nov; 9 Suppl 5():S29-35. PubMed ID: 8583478
[TBL] [Abstract][Full Text] [Related]
8. Losartan potassium as initial therapy in patients with severe hypertension.
Dunlay MC; Fitzpatrick V; Chrysant S; Francischetti EA; Goldberg AI; Sweet CS
J Hum Hypertens; 1995 Nov; 9(11):861-7. PubMed ID: 8583463
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies.
Lee H; Yang HM; Lee HY; Kim JJ; Choi DJ; Seung KB; Jeon ES; Ha JW; Rim SJ; Park JB; Shin JH; Oh BH
Clin Ther; 2012 Jun; 34(6):1273-89. PubMed ID: 22608107
[TBL] [Abstract][Full Text] [Related]
11. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
[TBL] [Abstract][Full Text] [Related]
12. Alterations in vascular structure and function after short-term losartan treatment in spontaneously hypertensive rats.
Soltis EE
J Pharmacol Exp Ther; 1993 Aug; 266(2):642-6. PubMed ID: 8355197
[TBL] [Abstract][Full Text] [Related]
13. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the antihypertensive effects of the fixed dose combination enalapril 10 mg/nitrendipine 20 mg vs losartan 50 mg/hydrochlorothiazide 12.5 mg, assessed by 24-h ambulatory blood pressure monitoring, in essential hypertensive patients.
de la Sierra A; Gil-Extremera B; Calvo C; Campo C; García-Puig J; Márquez E; Oliván J; Roca Cusachs A; Sanz de Castro S; Pontes C; Delgadillo J
J Hum Hypertens; 2004 Mar; 18(3):215-22. PubMed ID: 14973517
[TBL] [Abstract][Full Text] [Related]
15. A multicenter, randomized, double-blind, parallel-group trial of the antihypertensive efficacy and tolerability of a combination of once-daily losartan 100 mg/hydrochlorothiazide 12.5 mg compared with losartan 100-mg monotherapy in the treatment of mild to severe essential hypertension.
Gleim GW; Rubino J; Zhang H; Shahinfar S; Soffer BA; Lyle PA; Littlejohn TW; Feig PU
Clin Ther; 2006 Oct; 28(10):1639-48. PubMed ID: 17157119
[TBL] [Abstract][Full Text] [Related]
16. [Antihypertensive effect of valsartan 80 mg and hydrochlorothiazide 12.5 mg evaluated by ambulatory blood pressure monitoring].
Vaïsse B; Ghobrial H; Vaur L; Poncelet P; Asmar R; Herpin D; Mallion JM
Arch Mal Coeur Vaiss; 2001 Aug; 94(8):907-12. PubMed ID: 11575229
[TBL] [Abstract][Full Text] [Related]
17. Effects of chronic treatment with losartan on blood pressure, endothelin-like immunoreactivity and nitric oxide in normotensive rats.
Sacerdote A; Cosenzi A; Bocin E; Molino R; Seculin P; Plazzotta N; Luxich E; Bellini G
J Hypertens; 1995 Dec; 13(12 Pt 2):1670-3. PubMed ID: 8903630
[TBL] [Abstract][Full Text] [Related]
18. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin II antagonists: a new class of antihypertensive agent.
Waeber B; Brunner HR
Br J Clin Pract; 1996; 50(5):265-8. PubMed ID: 8794603
[TBL] [Abstract][Full Text] [Related]
20. Acute myocardial and vascular responses to specific angiotensin II antagonism in the spontaneously hypertensive rat.
Cody RJ; Binkley PF; Haas GJ; Brown DM
Am J Hypertens; 1995 May; 8(5 Pt 1):500-8. PubMed ID: 7662227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
